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MANUSCRIPT:  
(Submitted for publication to the British Journal of Ophthalmology in June 2008) 
ABSTRACT: 
Background/Aims: 
To document baseline and longitudinal values for peripapillary retinal nerve fiber layer (RNFL) 
thickness, macular thickness, and macular volume as measured by optical coherence 
tomography(OCT) in glaucomatous and control eyes of children, followed prospectively for a 
mean of 2.4 years (range 0.5-5.3 years).   
Methods:   
OCT measurements (Fast RNFL 3.4 Thickness, Fast RNFL Map, and Fast Macular Thickness 
Map protocols; StratusOCT, Carl-Zeiss-Meditech, Dublin,CA) were obtained at baseline and on 
follow-up in 27 control and 19 glaucoma participants at the Duke University Eye Center 
Pediatric Clinic.  Longitudinal changes were compared between groups with a two-sample-t-test 
and multiple linear regression analysis of covariance model adjusting for age, race, and baseline 
refractive error.  
Results:  
Eyes with glaucoma exhibited reduced baseline macular thickness, macular volume, and RNFL 
thickness, and increased myopia, compared to control eyes (eg. macular volume 6.54 vs. 7.03 
mm
3
, p=0.006; RNFL 3.4 thickness 87.8 vs. 110.6µm, p=0.02).  All OCT parameters studied 
showed minimal change over time, and rates of change were similar between groups.   
Conclusion:  
 Baseline differences and longitudinal stability of OCT parameters were seen in normal and 
clinically stable glaucomatous eyes of children.  These findings support continued study of OCT 
as an easily performed clinical adjunct in evaluation and management of children with glaucoma. 
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INTRODUCTION: 
Pediatric glaucoma causes an estimated 9.5-10.8% of childhood visual impairment.[1, 2] 
If treated surgically and/or medically at an appropriately early stage, juvenile glaucoma’s 
negative effects can be lessened substantially.  If untreated, glaucoma can result in irreversible 
blindness.  Thus objective, sensitive ocular measurements are extremely valuable for early 
diagnosis, treatment, and measurement of disease progression in children with glaucoma.  
Optical Coherence Tomography (OCT), a rapid, non-invasive imaging technique, has 
been studied extensively in adult eyes with glaucoma and to a lesser extent in children.  It has 
been shown to have high inter-operator reproducibility,[3] reliably distinguish glaucomatous 
eyes from normals,[4] 
 
match the diagnostic efficacy of ONH stereophotography in early 
glaucoma,[5] 
 
have high sensitivity and specificity in measuring RNFL thickness,[6] predict 
future glaucomatous change,[7] and provide earlier detection of glaucomatous damage.[8]  
Baseline OCT and refractive error measurements have been studied in adult[7, 9] and 
pediatric[10, 11] glaucoma patients; longitudinal progression of OCT measurements[7, 12, 13] 
has been examined only in adults.  Baseline cross-sectional studies in adults have shown a 
correlation between glaucoma and decreased baseline RNFL, macular thickness, and macular 
volume;[6, 9, 14]  between increased myopia and decreased RNFL thickness[15] and between 
baseline RNFL thinning and future glaucomatous change.[7]  In children, glaucoma has been 
correlated with reduced baseline macular thickness and macular volume, increased myopia, and 
reduced RNFL thickness, particularly in the inferior quadrant.[10, 11, 16]    Longitudinal OCT 
monitoring in adults has shown either no difference,[12] or a slightly greater rate of RNFL 
thickness reduction,[13] in glaucomatous vs. control eyes in adults over time.   OCT 
measurements also have been shown to be affected by race, refractive error, axial length, and 
age: for example, decreased macular and RNFL thickness[17] in African American than 
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Caucasian individuals; thinner RNFL in Caucasian than Hispanic or Asian individuals;[18] and 
decreased RNFL thickness with increased age, axial length, and myopia.[18, 19]  Most studies in 
adults, and all studies in children, have been cross-sectional.  Prospective longitudinal OCT 
measurements have not been studied in children, nor has the longitudinal relationship between 
pediatric glaucoma and RNFL thinning been examined.   
We conducted a 6-year prospective study of 46 children aged 2 to 16 years old recruited 
from a pediatric ophthalmology clinic at a large academic medical center.  Our objective was to 
document longitudinal changes in OCT measurements of peripapillary RNFL thickness, macular 
thickness, and macular volume in glaucomatous vs. control eyes of children.  
 
MATERIALS AND METHODS: 
Study Participants:   
OCT measurements were completed in both eyes of 21 control participants, 6 participants 
with uniocular glaucoma (whose normal eyes were included in the control group), and 19 
participants with bilateral glaucoma, selected from the Duke University Eye Center Pediatric 
Clinic between December 2002 and August 2006.  Selection was by the attending physician 
caring for the patient (SFF).  Patients with glaucoma receiving OCT as part of their regular 
clinical care signed a consent allowing their measurements to be used in the study; control 
participants were patients with large physiological cups or normal volunteers who agreed to 
receive OCT measurements. Inclusion criteria for the glaucoma group included clinical diagnosis 
of glaucoma (elevated intraocular pressure, visual field loss, and optic nerve damage) and high 
quality of baseline and repeat scans; patients were excluded if they had media opacities, were 
unable to fixate, or had severe myopia (-4.0 diopters or greater).  Control participants were 
patients with normal intraocular pressure and no optic nerve damage or visual field loss. The 
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study was approved by the Duke University Medical Center Institutional Review Board; 
informed consent was obtained from the legal guardian of each child before study enrollment.   
Measures:   
OCT protocols performed included Fast RNFL 3.4 Thickness, Fast RNFL Map, and Fast 
Macular Thickness Map.(Figure 1)  Measurements were obtained at baseline and at one to four 
clinically-indicated visits for glaucoma or routine eye care during a mean 2.4 years of follow-up 
(range 0.5-5.3 years); demographic data and refractive error measurements were also recorded.  
The baseline and most recent measurements from the right eye of normal and bilateral glaucoma 
participants, and from the normal eye of uniocular glaucoma participants, were used for analysis.  
To account for unequal lengths of follow-up, and to provide a clinical context for each patient’s 
progression, outcomes were expressed as rates:  percent change per year (of each eye’s baseline 
value) and absolute change per year.  Three OCT machines were used (Stratus OCT, Carl-Zeiss-
Meditech, Dublin, CA); they are located in the Duke University Eye Center Photography 
Department and are frequently calibrated by the Department to minimize variability.  
Analysis:   
First the unadjusted outcomes [absolute and percent change per year in average RNFL 
3.4 thickness (µm), RNFL inner- and outer-ring thickness (µm), macular inner- and outer-ring 
thickness (µm), and macular volume (mm
3
)] were compared between glaucomatous and control 
eyes, using a two-sample t-test.  A multiple linear regression analysis of covariance (ANCOVA) 
model was then constructed for each outcome, adjusted for age (years), parent-reported race 
(white/black/other), and baseline refractive error (spherical equivalents).   
Since the eye expands and refractive error naturally increases with age in childhood, and 
some analyses have shown no effect of age after controlling for refraction,[19] a Pearson’s 
correlation coefficient was calculated between age and baseline refractive error within the model.   
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To determine whether OCT parameters were affected by length of follow-up, Pearson’s 
correlation coefficients were calculated between each outcome and follow-up time within the 
regression model.  To determine whether RNFL thickness was correlated with baseline refractive 
error as has been observed previously in adults,[15] a Pearson’s correlation coefficient was 
calculated between these two values within the regression model. 
RESULTS: 
Of the study’s 27 control participants, 6 (22%) had glaucoma in the other eye, 18 (67%) 
had large cups, and 3 (11%) had small cups.  Of the study’s 19 participants with glaucoma, 13 
(69%) had juvenile open-angle glaucoma (JOAG), 5 (26%) had congenital glaucoma, and 1 (5%) 
had secondary pseudophakic glaucoma.  All patients with glaucoma have been clinically stable 
during follow-up, established by optic nerve examination and visual field testing when possible.   
Mean age at baseline was 10.5 and 8.9 years for the glaucoma and control groups, 
respectively; racial and gender makeup of the two groups was comparable.  Mean follow-up was 
2.3 and 2.5 years for the glaucoma and control groups, respectively.(Table 1).  Baseline average 
RNFL 3.4 thickness, macular inner- and outer-ring thicknesses, and macular volume were 
significantly lower, and baseline refractive error was significantly greater, in glaucomatous vs. 
control eyes.  Baseline RNFL inner- and outer-ring thicknesses were reduced in glaucomatous 
vs. control eyes, but the difference was not significant.(Table 2).  
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FIGURE 1. 
 
 
 
TABLE 1. 
 
Participant characteristics: control and glaucomatous eyes (1 eye/participant) 
 Control  Glaucoma p-value 
Number of participants (n) 27 19  
Mean age at baseline (years) 
(95% CI) 
8.9  
(7.8,10.0) 
10.5  
(9.0, 12.0) 
0.07 
Mean follow-up (years) 
(95% CI) 
2.5  
(2.04, 2.92) 
2.3  
(1.65, 2.98) 
0.67 
Gender (male:female %) 44:56 42:58 0.88 
Race/Ethnicity (% white: black: other) 63:33:4 53:42:5 0.49 : 0.55 : 0.80 
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TABLE 2. 
 
Mean and 95% confidence interval of baseline ocular parameters: control and glaucomatous eyes 
Baseline ocular parameter Control  Glaucoma p-value 
Mean peripapillary RNFL thickness  
[µm, Fast RNFL 3.4 Thickness]  
110.6  
(104.0, 117.2) 
(n=15) 
87.8 
(60.1, 115.4) 
(n=7) 
0.02 
Mean RNFL Thickness, Inner Ring  
[µm, Fast RNFL Map] 
 
89.2 
(78.4, 99.9)  
(n=11) 
81.3 
(67.5, 95.1)  
(n=14) 
0.36 
Mean RNFL Thickness, Outer Ring  
[µm, Fast RNFL Map] 
 
69.3 
(59.5, 79.1) 
(n=11) 
62.6 
(50.2, 75.0) 
(n=13) 
0.38 
Mean macular thickness, Inner Ring  
[µm, Fast Macular Thickness Map] 
 
271.2  
(263.2, 279.2) 
(n=27) 
257.8  
(247.1, 268.4) 
(n=19) 
0.04 
Mean macular thickness, Outer Ring  
[µm, Fast Macular Thickness Map] 
243.2  
(235.2, 251.3) 
(n=27) 
225.3  
(215.1, 235.5) 
(n=19) 
0.006 
Mean macular volume  
[mm
3, 
Fast Macular Thickness Map] 
7.03 
(6.81, 7.25) 
(n=27)
 
6.54 
(6.27, 6.82) 
(n=19)
 
0.006 
Mean refractive error  
[spherical equivalents] 
-0.10  
(-0.78, 0.57) 
(n=27) 
-1.51  
(-2.21, -0.81) 
(n=19) 
0.006 
n=number of participants (1 eye/participant) for each OCT scan protocol. 
 
During a mean 2.4 years of follow-up, the six OCT parameters changed little, and rates of 
change between glaucomatous and control eyes were similar.(Table 3)  Age was significantly 
correlated with baseline refractive error (correlation coefficient -0.32, p = 0.03), so the 
ANCOVA regression model was run with both age and refractive error, and with refractive error 
only, in addition to race.  Results were similar; the model with all covariates is reported.(Table 3)   
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TABLE 3. 
 
Adjusted mean and range of OCT changes in control and glaucomatous eyes during a mean 2.4 
years of follow-up (ANCOVA regression model, adjusted for age, race, and baseline refractive 
error) 
 
Adjusted OCT 
parameter 
Absolute change (µm) per 
year (95% CI) 
Percent change per year 
from baseline  
(95% CI) 
 
p-value*  
 
Control  Glaucoma Control  Glaucoma 
Mean peripapillary RNFL 
thickness [µm, Fast 
RNFL 3.4 Thickness] 
-0.4  
(-3.5, 2.7) 
(n=14) 
4.3 
(-0.3, 8.9) 
(n=7) 
-0.1 
(-3.3, 3.0) 
(n=14) 
3.5   
(-1.2, 8.2) 
(n=7) 
0.25 
Mean RNFL Thickness, 
Inner Ring [µm, Fast 
RNFL Map] 
2.6 
(-1.4, 6.6) 
(n=11) 
0.03 
(-3.6, 3.6) 
(n=13) 
3.4 
(-2.1, 9.0) 
(n=11) 
0.2 
(-4.8, 5.2) 
(n=13) 
0.47 
Mean RNFL Thickness, 
Outer Ring [µm, Fast 
RNFL Map] 
2.4 
(-3.3, 8.1) 
(n=11) 
-2.3 
(-7.7, 3.0) 
(n=12) 
5.3 
(-3.8, 14.5) 
(n=11) 
-1.0 
(-9.7, 7.6) 
(n=12) 
0.39 
Mean macular thickness,  
Inner Ring [µm, Fast 
Macular Thickness Map] 
1.4  
(-0.9, 3.6) 
(n=27) 
0.7  
(-2.1, 3.5) 
(n=18) 
0.5  
(-0.4, 1.4) 
(n=27) 
0.3 
(-0.8, 1.3) 
(n=18) 
0.73 
Mean macular thickness,  
Outer Ring [µm, Fast 
Macular Thickness Map] 
-0.4  
(-1.8, 0.9) 
(n=27) 
1.7 
(-0.05, 3.4) 
(n=18) 
-0.2  
(-0.7, 0.4) 
(n=27) 
0.7   
(-0.02, 1.4) 
(n=18) 
0.08 
Mean macular volume  
[mm
3
, Fast Macular 
Thickness Map] 
-0.02 
(-0.06, 0.03) 
(n=27) 
0.05 
(-0.004, 0.1) 
(n=18) 
-0.2   
(-0.8, 0.4) 
(n=27) 
0.7   
(-0.1, 1.5) 
(n=18) 
0.10 
n=number of participants (1 eye/participant) for each OCT scan protocol. 
* p-value for difference between glaucomatous and control eyes, in percent change per year from 
each eye’s baseline.   
 
 
There was no significant correlation between the rate of change in any of the 6 OCT 
parameters and follow-up time in the regression model.  There was also no significant 
relationship between average RNFL 3.4 thickness and baseline refractive error (correlation 
coefficient 0.35, p=0.11). 
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DISCUSSION: 
In this prospective study of children aged 2 to 16 with glaucoma, glaucomatous eyes 
exhibited reduced baseline RNFL thickness, macular thickness, and macular volume, and 
increased baseline myopia, compared to control eyes.  During a mean 2.4 years of follow-up, 
OCT measurements in control and glaucomatous eyes changed minimally.  Annual changes 
ranged from -0.4µm/year (for macular outer-ring thickness) to 4.3µm/year (for average RNFL 
3.4 thickness), clinically modest amounts in the context of OCT’s intra-eye variability of 3.14µm 
for Fast Macular Thickness protocol and 2.68µm for Fast RNFL 3.4 Thickness protocol.[3]  To 
our knowledge, this is the first study to prospectively analyze longitudinal changes in OCT 
measurements of peripapillary RNFL thickness, macular thickness, and macular volume in 
children with and without glaucoma.   
The rates of change for the six OCT parameters were similar between control and 
glaucomatous eyes, adjusted for age, race, and baseline refractive error.  There was also no 
correlation between change in OCT parameters and length of follow-up (i.e. participants with 
long and short follow-up showed similar rates of change).  Furthermore, since the expected axial 
length increase in children older than 10 years is 0.4-0.5mm over 8 years (10-18 years old),[20] 
and average RNFL thickness decreases by 2.2µm for every 1mm increase in axial length,[18, 21] 
adolescent axial length increase would be expected to account for no more than about 1.1 µm 
decrease in OCT measurements of average RNFL thickness over 8 years.    
The present study is consistent with previous published studies reporting decreased 
baseline RNFL thickness, macular thickness, macular volume, and increased baseline myopia in 
glaucomatous vs. control eyes.[6, 9-12, 15]  Consistent with longitudinal findings in adults,[12] 
longitudinal changes in RNFL thickness, macular thickness, and macular volume were similar in 
glaucomatous and control eyes in our population.  However, unlike in previous adult findings,[7] 
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decreased baseline RNFL thickness in our population was not predictive of future RNFL 
thinning.  There are several potential explanations for our findings.   
The limited length of time between baseline and subsequent OCT measurements in our 
study might be insufficient to detect ongoing glaucomatous changes in OCT parameters such as 
RNFL and macular thickness.  Second, the present study included eyes of children whose 
glaucoma was clinically stable; the stable OCT measurements in these eyes would seem to 
confirm the clinical impression of disease control over the study period.  Third, and likely most 
important, the limited number of eyes in the present study limits its power to detect small 
differences between study groups.  Additionally, many eyes in the control group had been 
referred to our practice as glaucoma suspects based upon optic nerve cups, biasing the study 
toward more similarity between glaucoma and control groups than otherwise might be observed.    
Furthermore, many children with severe glaucoma could not be included in the study because of 
media opacities or poor fixation.  These eyes with severe glaucoma might have demonstrated 
higher rates of decline in OCT parameters than the stable glaucomatous eyes included in the 
study.   This is particularly important given the potentially proportional relationship between 
disease progression and ocular changes, as has been shown with macular volume.[18] 
There are several additional limitations to the present study.  The patients attending the 
Duke University Eye Center, a research-focused tertiary care center, may not be representative of 
the general population, thus reducing generalizability of results.  Data were collected as part of 
normal clinic visits, so participants, clinicians, and data collectors were unmasked.  Baseline and 
repeat OCT measurements were completed by different operators, introducing potential 
measurement bias, although such bias is likely small due to OCT’s high inter-operator 
reproducibility[4] and frequent on-site calibration.   The study would have been stronger if it 
included more patients, OCT reproducibility data, and axial-length measurements.   
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The present study has examined longitudinal changes in OCT measurements of 
peripapillary RNFL thickness, macular thickness, and macular volume in children with and 
without glaucoma.  While confirming previously reported baseline differences between 
glaucomatous and control eyes in children,[10, 11] we found that longitudinal OCT parameters 
were essentially stable in both groups, with similar, minimal rates of change over a relatively 
short time period.  Despite its limitations, our findings support continued study of OCT as an 
easily performed clinical adjunct in the evaluation and management of children with glaucoma.   
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NON-MANUSCRIPT ADDENDA, UNC MPH THESIS: 
 
Research Question:   
Do children with glaucoma exhibit greater changes in peripapillary RNFL thickness, macular 
thickness, and macular volume [as measured by Optical Coherence Tomography (OCT)] 
compared to non-glaucomatous children during a mean 2.4 years of follow-up?  
Hypothesis:   
We expect OCT measurements of ocular parameters to reflect those in the adult population: that 
is, to show an association between glaucoma and reduced baseline and longitudinal RNFL 
thickness, reduced baseline and longitudinal macular volume, and greater baseline refractive 
error.   Thus we hypothesize that our study’s participants with glaucoma will have lower baseline 
RNFL thickness, macular inner- and outer-ring thicknesses, and macular volume, and higher 
baseline refractive error, than control participants.  During follow-up, we expect glaucomatous 
eyes to exhibit greater decreases in peripapillary retinal nerve fiber layer (RNFL) thickness, 
inner- and outer-ring retinal thicknesses, inner- and outer-ring macular thicknesses, and macular 
volume than control participants.   
 
Addendum to Abstract (see page 1): 
Background/Aims: 
This study documents baseline and longitudinal OCT measurements in control and glaucomatous 
eyes of children. If clinically meaningful inter-group differences exist, this would support the use 
of OCT to assist with noninvasive baseline glaucoma diagnosis, and/or to monitor subclinical 
glaucoma progression over time.  If we identify longitudinal stability, this could suggest the use 
of OCT in monitoring maintenance of RNFL over time, the ability of attentive medical 
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management to prevent retinal thinning in children with glaucoma, or the limitations of the 
study’s small sample size. 
 
Addendum to Introduction (see page 2): 
Burden of Disease: 
Glaucoma is the leading cause of preventable blindness in the United States, and the 
second leading cause of bilateral blindness in the world. 1, 2   One form of the disease, pediatric 
glaucoma, causes an estimated 9.5%-10.8% of childhood visual impairment 3, 4 and occurs as 
congenital glaucoma or juvenile open-angle glaucoma (JOAG), or can be secondary to syndrome 
complexes, medications, chemical and physical trauma, cataract surgery and pseudophakia, or 
other ocular pathologies.   
High intraocular pressure can permanently damage the optic nerve, and can distend and 
thin the cornea and sclera.
5, 6 
  Due to more elastic ocular collagen, corneal and scleral thinning 
are even more pronounced in children younger than 3 years of age, making early diagnosis even 
more important in these children.  40% of patients with infantile glaucoma have symptoms at 
birth, and 86% by 1 year of age;
7
 however, the age of medical diagnosis for children with later-
onset JOAG ranges from birth until late childhood.   
Disease Etiology: 
The etiology of congenital and juvenile open-angle glaucoma, like adult glaucoma, 
remains unclear.  These progressive conditions can be caused by abnormal fetal development of 
ocular angle structures, leading to impaired drainage of the aqueous fluid and elevated 
intraocular pressure (IOP).  The disease is also thought to be highly influenced by additive 
genetic effects, with heritability estimates of 35% for IOP, 48% for RNFL thickness, and 39% 
for neuroretinal rim area, and nongenetic factors accounting for only 13% of the variance in 
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these traits.
8
  Mutations in genes affecting angle development, such as in CYP1B1 (a member of 
the cytochrome P450 superfamily of enzymes), have been correlated with the degree of angle 
dysgenesis, age of onset, and difficulty of achieving intraocular pressure control.
8
   In some 
populations, mutations in this gene accounted for 37.5-70% of primary congenital glaucoma 
cases.
9-11
    
Pediatric glaucoma can also occur secondary to syndrome complexes, medications, 
chemical and physical trauma, cataract surgery and pseudophakia, or other ocular pathologies.  A 
prime example of glaucoma within a syndrome complex is Sturge-Weber syndrome (also known 
as encephalotrigeminal angiomatosis), a rare congenital neurological and skin disorder caused by 
a cerebral arteriovenous malformation.  Most often unilateral, it is associated with glaucoma, 
port-wine stains of the face, mental retardation, seizures, and leptomeningeal angioma.  Many 
medications (eg. topical steroid eye drops) can reduce aqueous humor drainage and thereby 
cause ocular hypertension and raise an individual’s risk of developing glaucoma; infants and 
very young children are particularly sensitive to this pressure rise.
12
  Chemical or physical 
trauma can cause corneal inflammation, hemorrhage, or lens dislocation or rupture, all producing 
a secondary pressure increase.  Cataract surgery in pediatric patients, with or without intraocular 
lens implant (pseudophakia and aphakia, respectively), is associated with glaucoma.
13
  In 
particular, early surgery (at <9 months of age) has a 7.2-fold increased risk of glaucoma 
compared with later surgery (>9 months of age), a higher risk that continues for more than 10 
years after cataract surgery.
14
  Other ocular pathologies such as tumors (eg. retinoblastoma), 
uveitis, iridocyclitis, or Coats’ Disease also can affect aqueous drainage and raise intraocular 
pressure.
 15-17
   
Tools for Glaucoma Diagnosis and Management: 
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The three most commonly used glaucoma diagnostic techniques are visual field testing, 
optic nerve head (ONH) stereophotography, and measurement of intraocular pressure (IOP) (see 
page 2).   Visual field testing takes 7-10 minutes per eye and requires significant concentration 
from the patient, making it unreliable in young children and those with nystagmus; in addition, it 
only shows changes in advanced stages of the disease.
18
   ONH stereophotography (the gold 
standard in adults) has high inter-observer variability.19   IOP measurements are completed via 
applanation or indentation tonometry, can vary substantially within one day in the same patient, 
and provide no information about retinal thinning or optic nerve damage.  In addition, 
applanation measurements are dependent upon central corneal thickness (CCT),
20
 yielding IOP 
deviation up to 7 mm Hg from the true IOP for every 100-µm variation in CCT from the normal 
CCT of 520 µm for which the tonometer is calibrated.
20, 21
  This biases toward glaucoma 
overdiagosis in patients with thicker CCT, and underdiagnosis of patients with thinner CCT. 
In addition to the above three modalities, several imaging techniques have emerged for 
evaluating and managing glaucoma, including optical coherence tomography (OCT), Heidelberg 
retinal tomography, and scanning laser polarimetry.  Since its introduction into adult and 
pediatric clinical practice in the past two decades,22  OCT has rapidly become a valuable tool for 
providing high-resolution cross-sectional tomographic images of the ocular microstructure (see 
page 2).  
First devised with 30µm axial resolution by Huang et al. in 1991, OCT’s initial 
application was in diagnosing and monitoring glaucoma;
23
 today OCT has sub-micrometer 
resolution and is used for other ophthalmic pathologies in addition to glaucoma, such as macular 
degeneration, retinal capillary hemangioma, macular edema in diabetes or retinal vein occlusion, 
retinal thinning in drug-induced retinal toxicity, central corneal thickness changes, and foveal 
and retinal detachment.  Studies have shown OCT to yield accurate, reproducible results when 
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used independently and/or in conjunction with other ophthalmic diagnostic technologies such as 
stereoscopic fundus photography, visual field testing, static automated pachymetry (SAP), and 
biomicroscopy.
24-26
  Other ophthalmic variations of traditional OCT technology include the OCT 
ophthalmoscope for en face OCT images of retinal diseases,
27
 and anterior segment OCT for 
evaluation of the cornea and anterior segment before and after lamellar transplantation surgery.
28
  
OCT is also used in non-ophthalmic tissue imaging requiring micrometer resolution and 
millimeter penetration depth: for example, hard and soft dental tissues;
29
 skin layers in 
inflammatory dermatologic disorders such as contact dermatitis and psoriasis;
30
 and 
preneoplastic lesions and epithelial changes in the esophagus, esophagogastric junction, 
duodenum, colon, and pancreatico-biliary ductal system.
31
   Currently it is also being 
investigated for use in imaging allergic and infectious changes in nasal mucosa;
32
 proximal 
airway microstructure changes in adult respiratory diseases;
33
 normal and pathologic features of 
the pediatric airway;
34
 and features of atherosclerotic plaques that predict plaque rupture, 
including fibrous cap thickness, lipid core size, and percentage of lipid content.
35, 36
  Outside 
medicine, OCT is used in art conservation projects to non-invasively analyze different layers of 
underdrawings in museum paintings.
37
       
Despite the promise of OCT as a useful adjunct in the clinical management of glaucoma, 
several potential problems exist.  These include variable reproducibility of measurements 
depending on quadrant measured,38 variable inter-individual reproducibility depending on 
protocol applied,22 and differences in measurements depending on OCT instrument used (eg. 
OCT 2000 vs. Stratus OCT/OCT3).39   In addition, although OCT performed better than ONH 
stereophotography in early detection of glaucomatous damage in perimetrically normal eyes of 
primary open-angle glaucoma patients (sensitivity 61% vs. 28%, respectively, with 95% 
specificity), 61% is still far from an optimal sensitivity value. 40   As with any technology, OCT 
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imaging may fail to identify true positives or may falsely identify glaucoma and its progression; 
thus clinicians should not make treatment decisions based on the results of a single test or 
technology.  Due to OCT’s relatively recent introduction into clinical practice, the efficacy of 
OCT in monitoring long-term disease progression has not been thoroughly demonstrated.  In 
addition, although OCT has shown to be an extremely safe, noninvasive imaging modality, there 
may be unforeseen adverse consequences of multiple ocular exposures to ultrasound over time; 
such consequences may only become apparent after several decades of routine OCT use. 
Glaucoma Treatment: 
Treatment for pediatric glaucoma can be medical and/or surgical, with medications 
(typically given as eye drops) usually tried before surgery.  The objective of most medications is 
to decrease intraocular pressure, the only treatment that has been proven effective in preventing 
the onset or progression of glaucoma.
41
  Medications achieve IOP reduction either by reducing 
aqueous humor production or increasing uveoscleral or transcanalicular aqueous humor outflow.  
The vast majority of medication data are from adult studies, and almost all of the drugs are not 
officially licensed for use in children,
42
 nor do they have pediatric safety labeling information.
43
  
However, most topical drugs have shown to be safe and well-tolerated in children.  These drugs 
include beta-blockers (eg. timolol), adrenergic α2-receptor agonists, and carbonic anhydrase 
inhibitors (e. acetazolamide), which inhibit aqueous humor formation; prostaglandin analogs (eg. 
latanoprost) and adrenergic a1-receptor antagonists, which increase uveoscleral aqueous humor 
outflow; and miotics (eg. pilocarpine), which increase transcanalicular aqueous humor 
outflow.
44, 45
  A notable exception to medication safety is the selective α2-receptor agonist 
brimonidine, a commonly used and well-tolerated glaucoma medication in adults, which can 
produce systemic effects such as apnea, bradycardia, bronchospasm, and hypotension in children 
under two years of age.
42, 46
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   The impact of  IOP reduction (via IOP-lowering medication) on RNFL thickness in 
newly-diagnosed adult glaucomatous patients has been equivocal, varying from no effect to a 
significant protective effect on RNFL thickness.
47, 48
  The relationship between IOP reduction by 
different ophthalmic medications and  degree of RNFL thinning has been examined in adults, 
with brimonidine appearing to have a more protective effect on RNFL thickness compared to 
timolol.
49
   Studies have differed in their findings of the effect of IOP reduction on optic nerve 
topography, showing that IOP reduction either has no effect on optic nerve topography 
changes,
50
 or that it moderately increases optic rim area and reduces optic cup area, cup volume, 
and cup-to-disk ratio.
51
   
In addition to established glaucoma medications, novel classes are currently under 
investigation.  For example, selective Rho-associated coiled coil-forming protein kinase (ROCK) 
inhibitors, are the first medications to act directly on the trabecular meshwork; these medications 
inhibit formation of actin stress fibers and focal adhesions, thereby improving aqueous outflow.
45
  
A forefront example is the ophthalmic solution SNJ-1656, currently in its Phase 1 clinical trial.  
This medication has demonstrated effective reduction of intraocular pressure, but is associated 
with post-instillation hyperemia of the bulbar and palpebral conjunctiva,
45
 which may limit its 
use in both adults and children. 
If intraocular hypertension is unresponsive to medical therapy, it can cause increased 
retinal thinning and necessitate surgical treatment.  First-line procedures usually include 
trabeculotomy (surgical opening of the canal of Schlemm to treat glaucoma), trabeculectomy 
(removal of part of the trabecular meshwork to relieve high intraocular pressure), or 
trabeculoplasty (laser photocoagulation of the trabeular meshwork).  In some patients, variations 
of these procedures have also been successful, such as nonpenetrating external trabeculectomy, 
which has fewer risks and postoperative complications than traditional trabeculectomy;
52
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combined trabeculotomy-trabecolectomy, which has shown efficacy in reducing intraocular 
pressure in surgery-naïve patients;
53
 and viscotrabeculotomy (use of viscoelastic materials during 
trabeculectomy), which has shown higher success rates than classical trabeculotomy due to its 
reduction of postoperative hemorrhage, adhesion of incision lips, or fibroblastic proliferation.
54
   
Further surgical treatment can include implantation of an Ahmed glaucoma valve (New World 
Medical, Inc, Rancho Cucamonga, California, USA), which has been shown to reduce 
intraocular pressure and number of necessary ophthalmic medications in patients with refractory 
pediatric glaucoma,
55
 and has shown long-term success (particularly when combined with 
glaucoma medications) in patients with uveitic glaucoma.
56
 
 
Addendum to Materials and Methods (see page 4): 
 
Measures: 
 
Optical coherence tomography (OCT) provides a non-contact measurement of retinal 
thickness using optical ultrasound.  It is less sensitive to opacities in the media than the earlier-
used retinal thickness analyzer (RTA), and may allow changes to be detected earlier in certain 
patients; it also provides quantitative measurements such as retinal nerve fiber layer thickness.  
OCT analysis itself involves pupil dilation (part of routine eye exam) followed by obtaining 
several cross-sectional retinal images by asking the patient to look into the instrument at different 
internal fixation targets.  Each cross-sectional set of images takes 200 msec to perform, and the 
total time required for the entire examination is approximately 2 minutes. An example of an OCT 
report is shown below.
57
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 To account for unequal lengths of follow-up between participants, and to address both 
statistical and clinical significance of OCT changes, outcomes were expressed as percent change 
per year (of each eye’s baseline value) in addition to absolute change per year.  This provides a 
clinical context for each patient’s progression; for example, a thinning of 10µm is more clinically 
concerning in a patient with baseline RNFL thickness of 50µm than in a patient with baseline 
RNFL thickness of 120µm.   
 In interpreting the results of our study, there are three potential outcomes: statistical and 
clinical significance, statistical significance but clinical insignificance, and statistical and clinical 
insignificance.  Given the absence of longitudinal research in pediatric glaucoma, all three 
scenarios – including a null outcome - are helpful, as they help us document expected values for 
change over time in glaucomatous and non-glaucomatous children.  A finding of statistical and 
clinical significance would support OCT’s use in providing reliable baseline glaucoma diagnosis 
as well as monitoring longitudinal disease progression.  In cases of statistical significance but 
clinical insignificance, we can conclude that the study had adequate power to detect small 
differences in ocular outcomes, but that these differences were not clinically meaningful.  A 
finding of statistical and clinical insignificance indicates no difference in ocular outcomes 
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between glaucomatous and control participants; such a finding could have several implications, 
including a different etiologic mechanism for pediatric and adult glaucoma, an opportunity for 
medical management to halt glaucomatous damage, a limited sample size, bias toward similarity 
between control and glaucomatous participants, or longitudinal regression to the mean. 
Analysis:   
The inclusion of age, race, and baseline refractive error as covariates in the ANCOVA regression 
model was due to the known effect of these factors on OCT measurements (see page 2); it also 
results in a thorough yet parsimonious model, remaining consistent with the advised limitation of 
number of model parameters per study case.
58
  
 
Addendum to Results (see page 8): 
TABLE 4. 
Unadjusted mean and range of OCT changes in control and glaucomatous eyes during a mean 
2.4 years of follow-up (two-sample t-test) 
 
Unadjusted OCT 
parameter 
Absolute change (µm) per 
year (95% CI) 
Percent change per year 
from baseline  
(95% CI) 
 
p-value*  
 
Control  Glaucoma Control  Glaucoma 
Mean peripapillary RNFL 
thickness [µm, Fast 
RNFL 3.4 Thickness] 
-0.6  
(-3.7, 2.5) 
(n=14) 
4.7 
(0.4, 9.1) 
(n=7) 
-0.3 
(-3.3, 3.0) 
(n=14) 
3.9   
(-0.6, 8.5) 
(n=7) 
0.15 
Mean RNFL Thickness, 
Inner Ring [µm, Fast 
RNFL Map] 
2.0 
(-2.3, 6.2) 
(n=11) 
2.1 
(-1.7, 5.8) 
(n=14) 
3.0 
(-2.7, 8.6) 
(n=11) 
2.5 
(-2.5, 7.5) 
(n=14) 
0.91 
Mean RNFL Thickness, 
Outer Ring [µm, Fast 
RNFL Map] 
0.7 
(-4.5, 5.9) 
(n=11) 
-0.3 
(-5.1, 4.5) 
(n=13) 
2.2 
(-5.9, 10.3) 
(n=11) 
2.4 
(-5.0, 9.8) 
(n=13) 
0.97 
Mean macular thickness,  
Inner Ring [µm, Fast 
Macular Thickness Map] 
1.7  
(-0.4, 3.7) 
(n=27) 
0.3  
(-2.2, 2.7) 
(n=19) 
0.6  
(-0.2, 1.4) 
(n=27) 
0.1 
(-0.8, 1.0) 
(n=19) 
0.41 
Mean macular thickness,  
Outer Ring [µm, Fast 
Macular Thickness Map] 
0.1  
(-1.2, 1.5) 
(n=27) 
0.9 
(-0.7, 2.5) 
(n=19) 
0.1  
(-0.5, 0.6) 
(n=27) 
0.4   
(-0.3, 1.1) 
(n=19) 
0.49 
Mean macular volume  
[mm
3
, Fast Macular 
-0.002 
(-0.04, 0.04) 
0.02 
(-0.03, 0.1) 
0.03   
(-0.6, 0.6) 
0.3   
(-0.4, 1.1) 
0.55 
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Thickness Map] (n=27) (n=19) (n=27) (n=19) 
n=number of participants (1 eye/participant) for each OCT scan protocol. 
* p-value for difference between glaucomatous and control eyes, in percent change per year from 
each eye’s baseline.   
 
Methods for Systematic Review of the Literature: 
We searched the MEDLINE/PubMed database (August 1983 to May 2008) using the 
following search terms: “childhood blindness U.S.” and “congenital glaucoma prevalence” for 
articles on congenital glaucoma’s burden of disease; “congenital glaucoma retina,” “congenital 
glaucoma refractive error,” and “infantile glaucoma” for articles on baseline ocular 
characteristics of pediatric glaucoma patients; “glaucoma optical coherence tomography,” 
“congenital glaucoma diagnosis,” and “glaucoma diagnosis retinal thickness” for articles on 
congenital glaucoma diagnosis; “glaucoma treatment,” “congenital glaucoma treatment,” 
“congenital glaucoma treatment trabeculectomy,” “congenital glaucoma medication,” “glaucoma 
medication,” and “glaucoma drugs” for articles on medical and surgical management of 
glaucoma; “glaucoma progression retinal thickness,” “glaucoma progression macular thickness,” 
“congenital glaucoma outcome,” “glaucoma progression optical coherence tomography,” and 
“RNFL decrease OCT” for articles on longitudinal glaucoma progression; “intraocular pressure 
medications retinal thickness,” “intraocular pressure retinal thickness,” “glaucoma retinal nerve 
fiber layer thickness,” “glaucoma macular thickness,” and “glaucoma retinal thickness OCT” for 
articles on the relationship between glaucoma and baseline RNFL and macular thickness; 
“optical coherence tomography uses” and “optical coherence tomography diagnosis accuracy” 
for articles on clinical uses and diagnostic reliability of OCT; “optical coherence tomography 
problem,” “optical coherence tomography resolution,” “optical coherence tomography resolution 
glaucoma,” “optical coherence tomography glaucoma adverse,” “optical coherence tomography 
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safety,” and “optical coherence tomography risk” for articles on potential problems with OCT 
technology; “secondary glaucoma children” and “secondary glaucoma children medication” for 
articles on the etiology of non-congenital glaucoma in children; “congenital glaucoma corneal 
thickness” for articles on the effect of glaucoma on corneal and scleral thickness; “congenital 
glaucoma gene” for articles on the molecular etiologies of glaucoma; “pediatric spherical 
equivalent change” for articles on eye development over time; “race retinal thickness”, “age 
retinal thickness”, and “refractive error retinal thickness” for articles on the influence of 
participant characteristics (covariates) on retinal thickness.   
We reviewed abstracts for citations in peer-reviewed journals, using the limits of age 
(Infant-18 years old), language (English), and subjects (human) for the majority of searches; for 
the OCT-problems, OCT-uses, OCT-accuracy, and some of the longitudinal OCT-parameters 
searches, no limits were applied.  For a detailed list of systematic search terms and limits, please 
refer to Table 5 in the Appendix.  We excluded the following:  studies of insufficient length to 
assess change in ocular outcomes (two months or less), studies that did not adjust for 
confounding variables (age, race), studies that did not include follow-up measures, and studies 
with a lack of glaucoma-related ocular outcomes.  Due to the small number of studies on 
pediatric ophthalmology patients, we considered all study designs except case reports and case 
series, and included articles with adult ophthalmology patients.  We then used a checklist, 
modified from two established quality assessment guidelines,
59, 60
 to evaluate the internal validity 
of scientific studies, systematic reviews, and meta-analyses that met the eligibility criteria.  For 
evidence grading checklist, please see Table 6 in the Appendix. 
In addition, we read several studies recommended to us by clinical or research professors.  
These included 3 articles on central corneal thickness and applanation tonometry, 1 article on 
glaucoma development after pediatric cataract surgery, 3 articles on the relationship between 
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axial length and retinal thickness, 2 articles including OCT reproducibility data, 1 article on 
ROCK inhibitors, 3 articles on translaminal pressure and glaucoma, 1 article on modeling and 
variable selection in epidemiologic analysis, 1 article including images of OCT reports, and 2 
articles on quality assessment guidelines. 
 
Addendum to Discussion (see page 9): 
 
Limitations: 
The present study has limited generalizability due to the tertiary-care, clinically complex 
patient population attending the Duke Eye Center, as discussed previously (see page 10).  In 
addition, it may be limited by selection bias, necessitating a discussion of the participant 
selection process.  Participants with glaucoma were selected sequentially; every patient with 
glaucoma between 2002 and 2006 who was able to fixate and had no media opacities was 
included in the study.  Control participants with large physiologic cups or uniocular glaucoma 
were also selected sequentially.  All control participants with normal cups were approached to 
participate in the study, and were included if they were willing to receive baseline and repeat 
OCT scans.  Since the Clinic sees relatively few patients with normal cups, and since selection 
largely depended upon the guardians’ willingness to allow their children to participate, these 
participants constitute somewhat of a “convenience sample.”  This could reduce the 
generalizability of the study findings, although this limitation is likely small considering that the 
control group only contained 3 participants (11% of group) with normal cups (see page 5).     
There are several factors that the present study was unable to evaluate as in previous 
studies (see page 2).  Since participants had longstanding diagnoses of glaucoma, the effect of 
IOP reduction on RNFL thickness in newly-diagnosed glaucoma could not be examined as has 
been done in previous studies.   Glaucoma treatment was not divided into separate IOP-lowering 
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medications, and thus the effect of specific medications on retinal thinning was not evaluated.  
Confocal scanning laser tomography was not completed in participants, so baseline and 
longitudinal changes in optic nerve topography could not be reported.  There were no previous 
studies of longitudinal change in macular thickness and macular volume, so we could not 
determine whether our findings were consistent with previously observed results.      
Specific to longitudinal studies of OCT measurements, it is important to consider both 
glaucomatous thinning and normal age-related eye growth.  Potential effects of the latter must be 
discerned from the former, through inclusion of age in regression analysis (see page 7), through 
demonstration of independence between outcome and follow-up time (see page 8), and/or 
through interpreting the results in the context of normal pediatric axial length increases (see page 
9).   
Increased axial length has been shown to be correlated with increased foveal thickness (in 
the central retina) and decreased parafoveal thickness;
61, 62
 these trends are present in both 
Caucasian and African American individuals, although they are more prominent in the latter, for 
unknown reasons.
63
  Thus it is not entirely surprising for our study to show a longitudinal 
increase in macular volume and macular inner-ring thickness in participants with increased 
refractive error (and presumably increased axial length) at baseline, i.e. in our study population’s 
participants with glaucoma (see page 8).  
Broader Implications: 
In analyzing the results of any study, it is important to evaluate the immediate hypothesis 
in question, but it is also imperative to think “outside the box” about potential explanations we 
had not previously considered.  For example, there are three main hypotheses of glaucoma 
etiology, each of which has developed out of innovative analysis and warrant further discussion 
in relation to our study findings.  One hypothesis is that the initial insult in glaucoma is optic 
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nerve damage, and that intraocular hypertension, retinal thinning, and increased refractive error 
are signs independently associated with this insult; this definition has led to the use of the phrase 
“optic neuropathy” to describe glaucoma, and helps explain why glaucoma occurs across the 
entire spectrum of intraocular pressure and often progresses despite normalization of IOP.
64
   
This hypothesis would account for the baseline differences in RNFL and macular thickness, 
macular volume, and refractive error seen between control and glaucomatous individuals in our 
study.  The lack of change in OCT parameters over time in our study counter this hypothesis, as 
an initial optic nerve insult would be expected to result in decreased OCT values in 
glaucomatous participants despite attainment of intraocular pressure control; however, since 
average follow-up was relatively short (2.4 years), it is difficult to say that a difference would not 
have been observed if the sample were followed for a longer time period.    
A second hypothesis, illustrated in a recent population-based case-control study, 
demonstrates a “tipping point” or paradigm shift in our understanding of glaucoma.64  The study 
showed that cerebrospinal fluid (CSF) pressure is significantly lower in patients with primary 
open-angle glaucoma, supporting the novel hypothesis that translaminal pressure difference – 
rather than absolute pressure values - may play an important role in the mechanism by which 
increased intraocular pressure causes optic nerve damage.
65
  The optic nerve is exposed to two 
different pressurized regions (intraocular space anteriorly, average IOP pressure 10-21 mmHg, 
and subarachnoid space posteriorly, average CSF pressure 5-15 mmHg), with the lamina cribrosa 
separating the two regions.
66
  If elevated, the pressure difference between them (the translaminar 
pressure difference) can cause optic nerve head swelling or optic nerve cupping: the former 
occurs when CSF pressure is elevated relative to IOP (eg. due to high CSF pressure in 
pseudotumor cerebri or low IOP in hypotony),
51, 67
 and the latter when IOP pressure is elevated 
relative to CSF (as in glaucoma).
68
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Indeed, the study showed that IOP, CSF pressure, and translaminal pressure difference all 
correlate with cup-to-disc ratio.
65
  It is also suggested that the high translaminar pressure gradient 
disrupts retinal ganglion cell axoplasmic flow, leading to retinal ganglion cell apoptosis and 
visual loss.
64
  This is supported by the observed kinking of retinal ganglion cell axons as they 
pass through the lamina cribrosa in the setting of elevated translaminal pressure difference, and 
the observation of reduced axonal transport at the lamina cribrosa in glaucoma models.
65
  It is 
also supported by the thinning and posterior bowing of the lamina cribrosa observed in 
glaucomatous human eyes.
69, 70
  The importance of pressure differences, rather than absolute 
values, in glaucoma pathogenesis is further underscored by studies in rabbits, which have shown 
that peripheral nerves can withstand high absolute pressures of 3800 mmHg, but show reduced 
axonal transport in the presence of a pressure gradient of only 4.5 mmHg.
71
 
Relating the above findings to our study, it is possible that the higher translaminal 
pressure difference seen in glaucoma – rather than the intraocular pressure alone – is the 
important factor in affecting the macula and retinal nerve fiber layer; this could account for the 
finding of lower baseline RNFL and macular thicknesses in glaucomatous than control 
participants.  It also could help explain the absence of longitudinal differences between the two 
groups: since glaucomatous participants’ intraocular pressure was kept at a near-healthy level 
with IOP-lowering medications, the translaminal pressure gradients of glaucomatous and control 
participants were likely quite similar.  Thus only the participants with inherently low CSF 
pressure would retain an elevated translaminal pressure gradient despite IOP reduction, and their 
results would likely be diluted within the aggregate glaucoma sample, thereby allowing the 
glaucomatous group’s change over time to remain similar to the control group’s change over 
time.   Although this hyopthesis is plausible, a more likely explanation is that the study’s sample 
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size was not large enough, and the follow-up period not long enough, to detect longitudinal 
differences between groups. 
A third hypothesis reflects an even broader view:  it is possible that retinal thinning, 
refractive error, and elevated IOP are all downstream manifestations of a common disease 
process involving innate differences in connective tissue makeup between glaucomatous and 
non-glaucomatous individuals.  Such differences suppose the ocular (and perhaps subarachnoid) 
connective tissue of the former to be more readily deformable than that of the latter.  This 
upstream mechanism could account for our study’s findings as well as for the aforementioned 
lower CSF pressure, elevated rates of myopia, lower central corneal thickness (CCT), and lower 
corneal hysteresis observed in glaucoma.   
The reasoning behind this hypothesis is as follows.   Corneal hysteresis is determined by 
the viscoelastic properties of the corneoscleral shell and thus is a useful indicator of the 
biomechanical properties of the eye; lower values are associated with more easily deformable 
corneoscleral coats, and have been reported to be associated with higher risk of glaucoma 
progression.
72
  A recent study in Chinese schoolchildren also showed a significant correlation 
between lower corneal hysteresis and longer axial length;
73
 the mean corneal hysteresis observed 
in the study was significantly lower than that previously reported in Caucasian children.
74
  This 
finding could help explain the higher prevalence and faster progression of myopia in Asian 
children than Caucasian children, since increased axial length is a major determinant of myopia 
development.  It also could explain the observed association between myopia and glaucoma,
75
 as 
a more compliant ocular coat could predispose individuals to axial elongation as well as provide 
less physical support for the optic nerve (and thus predispose to glaucoma progression).   
This more mechanical, rather than pressure-related, explanation for glaucomatous 
damage to the optic nerve is consistent with the fact that primary open-angle glaucoma occurs 
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across the entire spectrum of intraocular pressure, and that it often progresses despite 
normalization of IOP.
64
   It also could help explain why certain patients experience much greater 
optic nerve damage and visual field loss than other patients, despite having similar intraocular 
pressures.   
This third view counters the first hypothesis that optic neuropathy is the initial insult 
predisposing to elevated IOP, myopia, and retinal thinning.  It is consistent with the second 
hypothesis that an increased translaminal pressure gradient could lead to glaucoma, although it 
differs in its placement of that gradient along the causative disease pathway.  In contrast to the 
second hypothesis, increased IOP, axial elongation, myopia, and retinal thinning all could be 
manifestations of the same upstream mechanism in glaucomatous eyes – that of more pliable 
connective tissue makeup.  The lower CCT seen in glaucomatous eyes could be an additional 
manifestation of this increased biomechanical pliability.    
The finding by Berdahl et al. of lower CSF pressure and higher cup-to-disc ratio in 
glaucomatous vs. control individuals could be yet another downstream result of connective tissue 
differences.  It is possible that different biomechanical properties are reflected in subarachnoid 
drainage mechanics as well.  If this is the case, we would expect CSF protein and glucose levels 
to be similar in cases and controls, thereby indicating that CSF pressure differences are due to 
mechanics rather than metabolic processes involving CSF production by the cerebral ventricles 
or absorption by the arachnoid granulations over the venous sinuses.  Indeed, the study found 
this to be the case, hence supporting a mechanical rather than metabolic hypothesis.  This third 
hypothesis is consistent with the elevated rates of myopia, lower central corneal thickness 
(CCT), higher translaminal pressure difference, and lower corneal hysteresis observed in 
glaucoma, as well as the higher prevalence of myopia in the Asian population, and the 
association between lower corneal hysteresis and axial elongation.  Although plausible in adults, 
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it is necessary to demonstrate support for this hypothesis in children, whose ocular collagen is 
naturally more elastic than that in adults, and whose glaucoma etiology may be significantly 
different than that of adult glaucoma.  Unfortunately, to prove such a hypothesis, it would be 
necessary to measure CSF pressure and sample intraocular connective tissue concurrently with 
taking ocular measures, both of which are clinically impractical propositions.    
Public Health Application: 
In many cases a research study will apply to the general population and thus allow for 
public health interventions.  Given the rare incidence of pediatric glaucoma, population-based 
interventions are unlikely; however, the study’s results are very significant to the entire 
subpopulation of pediatric patients with glaucoma.  This includes patients with congenital 
glaucoma as well as JOAG and secondary glaucoma, since RNFL thinning is expected in all.  
The Duke University Eye Center Pediatric Clinic is a tertiary-care, referral-heavy institution, and 
thus sees a substantial number of the eastern U.S.’s pediatric glaucoma patients.  This referral 
pattern means that study participants are from varied regions across the Eastern U.S., which 
improves applicability to the general population; however, it also means that the study 
population likely has more complex glaucoma cases, more proactive families, and slightly higher 
socioeconomic status than that of the general pediatric glaucoma population.   In addition, 
Duke’s location in the Southeast gives the study a racial makeup of primarily African American 
and Caucasian individuals, thereby preventing direct comparison to demographically different 
populations, such as the Caucasian/Hispanic/Asian makeup of the U.S. West Coast.   
Future Studies:  
The relative paucity of research in pediatric ophthalmology is both daunting and exciting.  
Several short- and long-term steps in clinical research are needed to help us better understand 
pediatric glaucoma and improve care for patients.  The rare incidence of pediatric glaucoma 
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makes a randomized controlled trial unrealistic; however, prospective and retrospective case-
control study designs, such as in this study, would be both reasonable and cost-effective. 
Immediately, this study’s cohort could continue to be followed for several additional 
years; this would provide further information on longitudinal changes in RNFL and macular 
thicknesses and macular volume in children with and without glaucoma, and potentially establish 
reference ranges for expected OCT changes in patients with well-controlled glaucoma.   In 
addition, pharmaceutical companies could begin clinical trials on glaucoma medications in 
children, given that the vast majority of data are from adult studies and almost all the drugs are 
not licensed for use in children.  Pediatric use of adult medications is a major problem because 
ocular dosing is not weight-adjusted (thus giving children a much higher dose than is likely 
needed), infants’ incompletely-developed ocular apparatus cannot efficiently metabolize the 
medication, and drugs can more easily access the brain due to an immature blood-brain barrier.
42
  
Lower doses are likely just as efficacious and have a lower incidence of complications, such as 
the successful use of less-concentrated mitomycin-C in congenital glaucoma post-trabeculotomy 
patients.
76
  However, such studies are needed for other glaucoma medications commonly used in 
the pediatric population. 
 A longer-term research step could include completing a similar prospective longitudinal 
study of RNFL thickness, macular thickness, and macular volume change over time in a 
demographically distinct population: for example, with a primarily Hispanic, Asian, and 
Caucasian population on the U.S. West Coast.  Although we know that Hispanic and Asian 
individuals on average have higher RNFL thickness than Caucasians,
77
 longitudinal change has 
not yet been studied.  A second possibility would be to study longitudinal retinal thickness 
change in a highly myopic population, such as that of the Singapore Cohort study Of the Risk 
factors for Myopia (SCORM), a 1,250-participant study of the genes, genetic loci, and gene-
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environment interactions responsible for myopia in Singaporean children, who have some of the 
highest rates of myopia in the world.  Study of this cohort has shown a correlation between 
increased axial myopia and decreased retinal thickness at baseline;
78
 however, longitudinal 
changes have not been established for either the SCORM cohort or many other Asian study 
populations.  The Asian eye differs structurally from the Caucasian eye, as evidenced by the 
increased frequency, severity, and progression of myopia in the Asian population;
79-81
 the 
abovementioned difference in retinal thickness;
78
 and the earlier and more prevalent incidence of 
primary angle-closure glaucoma in Asian than in Caucasian individuals.
4, 82, 83
  These differences 
make Asia an opportune location for clinical trials on pediatric glaucoma.   In addition, 
previously identified myopia-related genes or newly-identified genes from the SCORM trial 
could be examined in future glaucoma studies, to determine if there is a common molecular 
etiology to both myopia and glaucoma in Asian and/or Caucasian populations. 
If greater retinal thinning over time is correlated with decreased visual acuity in patients 
with myopia, then OCT measurements potentially could be used as predictive biomarkers for 
vision loss.  This use of OCT would be relatively easy to implement, given that OCT is already 
widely used in the clinical setting for patients with various ocular pathologies; ophthalmologists 
would only have to incorporate its use for myopia in addition to these pathologies.  The approval 
of glaucoma medications for pediatric patients, once proven safe in pharmaceutical clinical trials, 
would necessitate FDA oversight and removal of the “NR” (not recommended) safety label from 
approved drugs.  Implementation of these medications will likely not alter clinical practice, given 
that they have been in use for many years without formal approval.  However, determination of 
proper weight-adjusted medication dosages for children, documentation of adverse systemic and 
ocular effects of certain drugs, and removal of unsafe medications from the market, would 
significantly improve clinical care by reducing complications in pediatric glaucoma patients.    
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APPENDIX: 
 
TABLE 5.  Systematic Review Literature Searches 
 
Date Database Main search terms Modifiers Yield 
(articles) 
Used 
search? 
2/11/08 PubMed Congenital glaucoma 
retina 
English 60  yes 
2/11/08 PubMed Congenital glaucoma 
retinal thinning 
English 2 no 
2/11/08 PubMed Congenital glaucoma English 1208 no 
2/11/08 PubMed Glaucoma optical 
coherence tomography 
English 367 yes 
2/11/08 PubMed Congenital glaucoma 
progression 
English 10 maybe 
2/11/08 PubMed Glaucoma progression 
retinal thickness 
English 66 yes 
2/11/08 PubMed Glaucoma diagnosis 
retinal thickness 
English 531 yes 
2/11/08 
 
PubMed Congenital glaucoma 
refractive error 
English 40 yes 
2/11/08 PubMed Congenital glaucoma 
diagnosis 
English 608 no 
2/13/08 PubMed Childhood blindness U.S. English 60 yes 
2/13/08 PubMed Congenital glaucoma 
prevalence 
English 86 yes 
2/16/08 PubMed Infantile glaucoma English, Infant-
18 yrs 
135 yes 
2/16/08 PubMed Congenital glaucoma 
outcome 
English, Infant-
18 yrs 
73 yes 
2/16/08 PubMed Glaucoma optical 
coherence tomography 
English, Infant-
18 yrs 
248 yes 
2/16/08 PubMed Glaucoma progression 
optical coherence 
tomography 
English, Infant-
18 yrs 
21 yes 
2/16/08 PubMed Congenital glaucoma 
diagnosis 
English, Infant-
18 yrs 
310  
(first 100 
reviewed) 
yes 
2/16/08 PubMed Congenital glaucoma 
refractive error 
English, Infant-
18 yrs 
22 no 
2/16/08 PubMed Glaucoma diagnosis 
retinal thickness 
English, Infant-
18 yrs 
383 (first 
60 
reviewed) 
yes 
2/22/08 PubMed Childhood myopia 
treatment glasses 
English, Infant-
18 yrs 
12 yes 
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3/1/08 PubMed Optical coherence 
tomography problem 
None 32 yes 
3/1/08 PubMed Optical coherence 
tomography resolution 
None 850 no 
3/1/08 PubMed Optical coherence 
tomography resolution 
glaucoma 
None 51 yes 
3/1/08 PubMed Optical coherence 
tomography glaucoma 
adverse 
None 33 no 
3/1/08 PubMed Optical coherence 
tomography safety 
None 134 (first 
60 
reviewed) 
no 
3/1/08 PubMed Optical coherence 
tomography risk 
None 161 (first 
40 
reviewed) 
no 
4/21/08 PubMed Secondary glaucoma 
children 
Humans, 
English, Infant-
18 yrs 
324 (first 
40 
reviewed) 
yes 
4/21/08 PubMed Secondary glaucoma 
children medication 
Humans, 
English, Infant-
18 yrs 
26 yes 
4/21/08 PubMed Congenital glaucoma 
corneal thickness 
Humans, 
English, Infant-
18 yrs 
6 yes 
4/21/08 PubMed Congenital glaucoma 
gene 
Humans, 
English, Infant-
18 yrs 
63 yes 
4/26/08 PubMed Pediatric spherical 
equivalent change 
None 8 yes 
4/26/08 PubMed Race retinal thickness None 49 yes 
4/26/08 PubMed Age retinal thickness Humans, 
English, Infant-
18 yrs 
115 
 
yes 
4/26/08 PubMed Refractive error retinal 
thickness 
None 31 yes 
4/27/08 PubMed Glaucoma treatment Humans, 
English, Infant-
18 yrs 
2243  
(first 40 
reviewed) 
yes 
4/27/08 PubMed Congenital glaucoma 
treatment 
Humans, 
English, Infant-
18 yrs 
237 yes 
4/27/08 PubMed Congenital glaucoma 
treatment trabeculectomy 
Humans, 
English, Infant-
18 yrs 
100 yes 
4/27/08 PubMed Congenital glaucoma Humans, 24 no 
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medication English, Infant-
18 yrs 
4/27/08 PubMed Glaucoma medication Humans, 
English, Infant-
18 yrs 
317 yes 
4/27/08 PubMed Glaucoma drugs Humans, 
English, Infant-
18 yrs 
206 yes 
4/28/08 PubMed Closed angle glaucoma 
Asia prevalence 
Humans, 
English, Infant-
18 yrs 
91 yes 
4/28/08 PubMed Intraocular pressure 
retinal thinning 
Humans, 
English, Infant-
18 yrs 
12 yes 
4/28/08 PubMed SCORM Humans, 
English, Infant-
18 yrs 
12 yes 
5/04/08 PubMed Optical coherence 
tomography diagnosis 
accuracy 
None 109 yes 
5/04/08 PubMed Optical coherence 
tomography uses 
None 91 yes 
5/10/08 PubMed Intraocular pressure 
medications retinal 
thickness 
None 17 yes 
5/10/08 PubMed Intraocular pressure 
retinal thickness 
None 436  
(first 60 
reviewed) 
yes 
5/11/08 PubMed Glaucoma retinal nerve 
fiber layer thickness 
Humans, Infant-
18 yrs 
42 yes 
5/11/08 PubMed Glaucoma macular 
thickness 
Humans, Infant-
18 yrs 
11 yes 
5/11/08 PubMed Glaucoma macular 
volume 
Humans, Infant-
18 yrs 
5 yes 
5/11/08 PubMed Glaucoma retinal 
thickness OCT 
Humans, Infant-
18 yrs 
18 yes 
5/11/08 PubMed Glaucoma progression 
retinal thickness 
Humans, Infant-
18 yrs 
7 yes 
5/11/08 PubMed Glaucoma progression 
macular thickness 
Humans, Infant-
18 yrs 
0 no 
5/11/08 PubMed Glaucoma progression Humans, Infant-
18 yrs 
136  
(first 40 
reviewed) 
no 
5/11/08 PubMed Myopia glaucoma risk None 144 yes 
5/11/08 PubMed Myopia glaucoma 
association 
None 48  
 
yes 
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5/26/08 PubMed OCT error None 94 yes 
5/29/08 PubMed RNFL decrease OCT  None 23 yes 
5/29/08 PubMed Macular volume increase 
OCT 
None 10 no 
 
 
TABLE 6.  Evidence Quality Scoring Checklist, modified from two established quality 
assessment guidelines
59, 60  
 
Level of review:      ______  Title  ______ Abstract ______ Article 
 
Study authors, citation, year:  
 
Type of Study:  
 
1. Is there description of the source population, including basic demographic and prognostic 
information?  
_____ YES (1)    _____ NO (0) 
 
 
2. Is the study population representative of the source population? 
_____ YES (1)    _____ NO (0) 
 
 
3. Is the measurement described and reliably ascertained? 
_____ YES, both (2)   ______ YES, described or ascertained (1)    _____ NO (0) 
 
 
4. Were case and control groups comparable on important confounding factors (age, race)? 
_____ YES (1)    _____ NO (0) 
 
 
5. Was there adjustment for the effects of these confounding variables? 
             _____ YES (1)    _____ NO (0) 
 
 
6. Was follow-up long enough for outcomes to occur (more than 2 months)? 
_____ YES (1)    _____ NO (0) 
 
 
7. Were the data collectors identified and masked? 
  _____ YES, both (2)    ______ YES, identified or masked (1)      _____ NO (0) 
 
 
8. Was statistical analysis completed? 
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_____ YES (1)    _____ NO (0) 
 
 
9. Were results reported thoroughly, including p-values and confidence intervals? 
_____ YES (1)    _____ NO (0) 
 
 
OVERALL QUALITY SCORE (maximum 11 points): 
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Original articles: 
1. Clinical Science: up to 2500 words, 5 images and tables, 25 references  
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1. Title  
2. Keywords (up to four) 
3. Addresses and which author address for correspondence 
4. Structured abstract 
(200 words, headings, "Background/aims", "Methods", "Results", and "Conclusion")  
5. Introduction  
6. Materials and methods 
7. Results  
8. Discussion  
9. References and acknowledgements  
10. Legends for display items (Figures and Tables)” 
 
Manuscript format: 
The manuscript format must be presented in the following order:  
1. Title page 
2. Abstract (or summary for case reports) 
3. Main text (tables should be inserted where cited in the text; images must be uploaded as 
separate files) 
4. Acknowledgments   Competing interests   Funding 
5. References 
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Do not use the automatic formatting features of your word processor such as endnotes, footnotes, 
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Images must not be embedded in the text file, but submitted as individual files. 
 
Statistics:    
Statistical analyses must explain the methods used.  
 
Tables: 
Tables should be submitted in the same format as your article and embedded in the main body of 
the article. Please note: Bench>Press cannot accept Excel files. If your table(s) are in Excel, copy 
and paste them into the manuscript file (where cited is preferable). In extreme circumstances, 
Excel files can be uploaded as supplementary files; however, we advise against this as they will 
not be acceptable if your article is accepted for publication.  Tables should be self-explanatory, 
and the data they contain must not be duplicated in the text or figures. 
 
References: 
Authors are responsible for the accuracy of references cited: these should be checked against the 
original documents before the paper is submitted. It is vital that the references are styled 
correctly so that they may be hyperlinked. 
In the text: 
References must be numbered sequentially as they appear in the text. References cited in figures 
or tables (or in their legends and footnotes) should be numbered according to the place in the text 
where that table or figure is first cited. Reference numbers in the text must be given in square 
brackets immediately after punctuation (with no word spacing) - for example, .[6] not [6]. 
Where more than one reference is cited, separate by a comma - e.g. [1, 4, 39]. For sequences of 
consecutive numbers give all numbers without spaces - for example, [22-25]. References 
provided in this format are translated during the production process to superscript type, which act 
as hyperlinks from the text to the quoted references in electronic forms of the article. 
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